Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenfluramine for CDKL5 deficiency disorder
MOH_2023-05-22_012662Phase 3Active, not recruiting
- Sponsor
- Zogenix, Inc.
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fenfluramine in CDKL5 deficiency disorder (CDD) (4 arms), sponsored by Zogenix, Inc. Started Mar 2023; status: active, not recruiting.
02
Drugs
fenfluramine
03
Conditions
CDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on MOH_2023-05-22_012662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-22_012662.